References
Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94(10):3315–3324
Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R, Warrell RP Jr (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol: Off J Am Soc Clin Oncol 19(18):3852–3860
Barbey JT, Pezzullo JC, Soignet SL (2003) Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol: Off J Am Soc Clin Oncol 21(19):3609–3615
Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Takeshita A, Sugiyama S, Satoh H, Terada H, Ohno R (2000) Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med 133(11):881–885
Kumana CR, Au WY, Lee NS, Kou M, Mak RW, Lam CW, Kwong YL (2002) Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies. Eur J Clin Pharmacol 58(8):521–526
Siu CW, Au WY, Yung C, Kumana CR, Lau CP, Kwong YL, Tse HF (2006) Effects of oral arsenic trioxide therapy on QT intervals in patients with acute promyelocytic leukemia: implications for long-term cardiac safety. Blood 108(1):103–106
Kathirgamanathan K, Angaran P, Lazo-Langner A, Gula LJ (2013) Cardiac conduction block at multiple levels caused by arsenic trioxide therapy. Can J Cardiol 29(1):130–e135-136
Drolet B, Simard C, Roden DM (2004) Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation 109(1):26–29
Hai JJ, Siu CW, Ho HH, Li SW, Lee S, Tse HF (2010) Relationship between changes in heart rate recovery after cardiac rehabilitation on cardiovascular mortality in patients with myocardial infarction. Heart Rhythm: Off J Heart Rhythm Soc 7(7):929–936
Siu CW, Pong V, Jim MH, Yue WS, Ho HH, Li SW, Lau CP, Tse HF (2010) Beta-blocker in post-myocardial infarct survivors with preserved left ventricular systolic function. Pacing Clin Electrophysiol: PACE 33(6):675–680
Yeung CY, Lam KS, Li SW, Lam KF, Tse HF, Siu CW (2012) Sudden cardiac death after myocardial infarction in type 2 diabetic patients with no residual myocardial ischemia. Diabetes Care 35(12):2564–2569
Siu CW, Pong V, Ho HH, Liu S, Lau CP, Li SW, Tse HF (2010) Are MADIT II criteria for implantable cardioverter defibrillator implantation appropriate for Chinese patients? J Cardiovasc Electrophysiol 21(3):231–235
Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG (2007) Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J 153(6):891–899
Consent
The patient agreed and consented for the case report to be published.
Conflict of interest
No authors have a real or perceived conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hai, J.J., Gill, H., Tse, HF. et al. Torsade de Pointes during oral arsenic trioxide therapy for acute promyelocytic leukemia in a patient with heart failure. Ann Hematol 94, 501–503 (2015). https://doi.org/10.1007/s00277-014-2174-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-014-2174-1